Date: 2015-06-10
Type of information: Nomination
Compound:
Company: Medgenics (USA - Israel)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 10, 2015, Medgenics, the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, announced the appointment of Barbara Duncan to the Company\'s Board of Directors effective July 22, 2015. Ms. Duncan has served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc. since May 2009. She previously served in a series of positions with increasing responsibilities at DOV Pharmaceuticals, Inc. including as Chief Executive Officer and Treasurer. Before that, she served as Vice President of Corporate Finance – Global Healthcare at Lehman Brothers Inc. and Director of Corporate Finance at SBC Warburg Dillon Read Inc. Ms. Duncan holds a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Bachelor of Business Administration from Louisiana State University.
Financial terms:
Latest news:
